Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Jun 1;90(11):2085-91.
doi: 10.1038/sj.bjc.6601856.

Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer

S Danson  1 , D Ferry, V Alakhov, J Margison, D Kerr, D Jowle, M Brampton, G Halbert, M Ranson
Affiliations

Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer

S Danson et al. Br J Cancer. .

Abstract

SP1049C is a novel anticancer agent containing doxorubicin and two nonionic pluronic block copolymers. In preclinical studies, SP1049C demonstrated increased efficacy compared to doxorubicin. The objectives of this first phase I study were to determine the toxicity profile, dose-limiting toxicity, maximum tolerated dose and pharmacokinetic profile of SP1049C, and to document any antitumour activity. The starting dose was 5 mg m(-2) (doxorubicin content) as an intravenous infusion once every 3 weeks for up to six cycles. A total of 26 patients received 78 courses at seven dose levels. The dose-limiting toxicity was myelosuppression and DLT was reached at 90 mg m(-2). The maximum tolerated dose was 70 mg m(-2) and is recommended for future trials. The pharmacokinetic profile of SP1049C showed a slower clearance than has been reported for conventional doxorubicin. Evidence of antitumour activity was seen in some patients with advanced resistant solid tumours. Phase II trials with this agent are now warranted to further define its antitumour activity and safety profile.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structures of (A) doxorubicin (B) block copolymers.
Figure 2
Figure 2
AUC vs dose level.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Alakhov V, Klinski E, Li S, Pietrzynski G, Venne A, Batrakova E, Bronich T, Kabanov A (1999) Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials. Colloids Surfaces B: Biointerfaces 16: 113–134
    1. Batrakova EV, Dorodonych TY, Klinski EY, Kliushnenkova EN, Shemchukova OB, Goncharova ON, Arjakov SA, Alakhov VY, Kabanov AV (1996) Anthracycline antibiotics, non-covalently incorporated into block copolymer micelles: in vivo evaluation of anti-cancer activity. Br J Cancer 74: 1545–1552 - PMC - PubMed
    1. Batrakova EV, Li S, Elmquist WF, Miller DW, Alakhov VY, Kabanov AV (2001) Mechanism of sensitisation of MDR cancer cells by Pluronic block copolymers: selective energy depletion. Br J Cancer 85(12): 1987–1997 - PMC - PubMed
    1. Bronchud MH, Margison M, Howell A, Lind M, Lucas SB, Wilkinson PM (1990) Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer. Cancer Chemother Pharmacol 25: 435–439 - PubMed
    1. Collet JH (2003) Poloxamers. In Handbook of Pharmaceutical Excipients, Rowe RC, Sheskey PJ, Weller PJ (eds) 4th edn. pp 447–450. Washington, DC: American Pharmaceutical Association

MeSH terms